Discovery and development of HIV-protease inhibitors - Wikipedia
HIV infects T cells that carry the CD4 antigen on their surface. When HIV infects its target cell it requires fusion of the ... The first reports of highly selective antagonists against the HIV protease were revealed in 1987. Phase I trials of saquinavir ... Tipranavir is a nonpeptidic HIV-1 protease inhibitor and reached the market in 2005. Unlike other HIV protease inhibitors on ... HIV protease inhibitors fit the active site of the HIV aspartic protease and were rationally designed utilizing knowledge of ...https://en.wikipedia.org/wiki/Discovery_and_development_of_HIV-protease_inhibitors
Subtypes of HIV - Wikipedia
... with the addition of CCR5 co-receptor antagonists and fusion inhibitors. Choice of initial and/or second-line therapy for HIV-2 ... HIV can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to viruses found in ... HIV superinfection HIV/AIDS research Discovery and development of CCR5 receptor antagonists History of HIV/AIDS Robertson DL, ... HIV/AIDS at Curlie (based on DMOZ) HIV Types at Avert.org 3D macromolecular structures of HIV-1 at the EM Data Bank(EMDB). ...https://en.wikipedia.org/wiki/Subtypes_of_HIV
Nanotechnology Approaches for Antiretroviral Drugs Delivery | Journal of AIDS and HIV Infections | Open Access Journals | Annex...
The advent of multidrug, highly active antiretroviral therapy (HAART), have increased the life span of HIV-infected patients. ... The development of effective drug delivery approaches for the treatment of AIDS and HIV infection is a global challenge. ... protease inhibitors (PIs); 5) fusion inhibitorsand 6) co-receptor antagonists. Moreover, FDA approved a combination of HIV ... 51 McGee B, Smith N, Aweeka F (2006) HIV pharmacology: Barriers to the eradication of HIV from the CNS. HIV Clin Trials 7: 142- ...http://www.annexpublishers.co/full-text/JAHI/1201/Nanotechnolog-Approaches-for-Antiretroviral-Drugs-Delivery.php
Viruses | Free Full-Text | Pharmacological Inhibition of Feline Immunodeficiency Virus (FIV) | HTML
Due to marked similarity in genomic organization, virus structure, virus replication and disease pathogenesis of FIV and HIV, ... inhibition of fusion of the virus membrane with the cell membrane; (3) blockade of reverse transcription of viral genomic RNA ... Anti-retroviral drugs studied extensively in HIV infection have targeted different steps of the virus replication cycle: (1) ... infection of cats with FIV is a useful tool to study and develop novel drugs and vaccines for HIV. ...http://www.mdpi.com/1999-4915/4/5/708/htm
How does ilex 15 interact with HIV medications?
... reported amongst HIV-positive people include: low potassium levels,. ... integrase inhibitors, entry inhibitors, fusion inhibitors, CCR5 receptor antagonists, maturation inhibitors, etc. The drugs ... In HIV and AIDS How do HIV medications affect the progression of HIV? HIV treatments must be promptly administered to anyone ... In HIV and AIDS Can medical labs transmit HIV? Your question is unclear. Should a laboratory deal with the HIV virus there ...http://www.answers.com/Q/How_does_ilex_15_interact_with_HIV_medications
CCR5 interaction with HIV-1 Env contributes to Env-induced depletion of CD4 T cells in vitro and in vivo | Retrovirology | Full...
HIV-1 fusion inhibitor T20 was used as negative control to prevent HIV-1 infection. b Graphical summary showing kinetics of CD4 ... CCR5 antagonist TAK-779 protects CD4 T cells from R3A-induced bystander CD4 T cell depletion. Expression of R5-tropic HIV-1 Env ... HIV-1 fusion inhibitor T20 treatment was used as negative control. c Kinetics of CD4 T cell depletion by R3A versus R3A-5/6AA ... 3d, 5c), corresponding with previous reports that the R3A Env fusion activity  and other HIV-1 proteins can promote death ...https://retrovirology.biomedcentral.com/articles/10.1186/s12977-016-0255-z
Flt-1 Intraceptor Induces the Unfolded Protein Response, Apoptotic Factors, and Regression of Murine Injury-Induced Corneal...
Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection. Mol Ther. ... VEGF antagonists. Expert Opin Biol Ther. 2001;1:703-718. [CrossRef] [PubMed] ... receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. ... Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy. Nat Med. 1997;3:1110-1116. [CrossRef] [PubMed ...http://iovs.arvojournals.org/article.aspx?articleid=2125152
Bernd Meyer : Current : Publications : Organic Chemistry : Universität Hamburg
Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Jan Münch, Ludger Ständker, ... Bioaffinity NMR spectroscopy: identification of an E-selectin antagonist in a substance mixture by transfer NOE. Dirk ... A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120. Axel T. Neffe, ... Synthesis and optimization of peptidomimetics as HIV entry inhibitors against the receptor protein CD4 using STD NMR and ligand ...https://www.chemie.uni-hamburg.de/oc/publikationen/Meyer_e.html
Inhibitors of Hepatitis C NS3 Protease - Patent application
CXCR4 antagonists (including but not limited to AMD-11070), fusion inhibitors (including but not limited to enfuvirtide ( ... invention with at least one of an HIV inhibitor, an HAV inhibitor and an HBV inhibitor. HIV inhibitors include agents ( ... Such agents can be selected from another anti-HCV agent; an HIV inhibitor; an HAV inhibitor; and an HBV inhibitor. Other ... HIV inhibitors include, but are not limited to: NRTIs (nucleoside or nucleotide reverse transcriptase inhibitors) ...http://www.patentsencyclopedia.com/app/20100087382
METHODS OF TREATING ALZHEIMER'S DISEASE AND OTHER TAUOPATHIES WITH INHIBITORS OF MICROTUBULE AFFINITY REGULATING KINASE - THE...
In particular, the invention relates to methods of treating Alzheimer's disease and other tauopathies with inhibitors of mi ... MKI Fusions with the Cell-Penetrating Peptide HIV TAT. The cell-penetrating peptide, trans-activator of transcription (TAT) of ... antagonists (e.g., Namenda® (memantine)), and small molecule inhibitors of MARK (e.g., pyrazolo(1,5-a)pyrimidine and ... The terms "fusion protein," "fusion polypeptide," or "fusion peptide" as used herein refer to a fusion comprising a cell- ...http://www.freepatentsonline.com/y2016/0030510.html
Indian Patents. 246027:'DIAZAINDOLE-DICARBONYL -PIPERAZINYL COMPOUND'
HIV infection AIDs, protease inhibitor. T^ Hi). Fuzeon (or T-20). Roche / Trimeris. HIV infection AIDs, viral Fusion inhibitor ... Chemokine receptor antagonists as HIV entry inhibitors. Expert Opinion on Therapeutic Patents (2004), 14(2;, 251-255.. ... HIV infection, AIDS, ARC. (RT inhibitor). Novapren. Novaferon Labs, Inc. (Akron, OH). HIV inhibitor. Peptide T. Octapeptide. ... HIV infection, AIDS, ARC. Ritonavir. Abbott. HIV infection, AIDS, ARC. (protease inhibitor). Saquinavir. Hoffmann-LaRoche. HIV ...http://www.allindianpatents.com/patents/246027-diazaindole-dicarbonyl-piperazinyl-compound
Investigating targets for a new class of anti-HIV drugs
... there is an urgent need for the discovery of a new class of anti-HIV drugs... ... prevent cell-to-cell fusion and block cell-associated transmission of HIV-1. ... They are now working to further develop more potent entry inhibitors from NBD-11021, with a higher selectivity index for pre- ... The team succeeded in transforming the full viral entry agonist NBD-556 to a full viral entry antagonist, NBD-11021, and ...http://researchfeatures.com/2016/11/01/investigating-targets-anti-hiv-drugs/
Patent US5668149 - Inhibition of human immunodeficiency virus-1 infectivity in human cells - Google Patents
The methods comprise contacting human cells infected with HIV-1, with certain quinolinyl and acridinyl derivatives, including ... Methods are disclosed for inhibiting the infectivity of HIV-1 in human cells. ... fusion inhibitors, and CD4-GP120 binding inhibitors. US7851600. 16 Oct 2006. 14 Dec 2010. Progenics Pharmaceuticals Inc.. Anti- ... infection through the administration of CCR5 chemokine receptor antagonists. ...http://www.google.ca/patents/US5668149
Patente US5486599 - Construction and use of synthetic constructs encoding syndecan - Google Patentes
HIV). However, these molecules are highly heterogenous and are probably non-specific. A more specific inhibitor would be a ... The fusion protein of claim 18, comprising a syndecan/basic FGF fusion protein represented by SEQ ID NO: 39. ... as either agonists or antagonists, as well as facilitate design of small molecule agonists and antagonists. ... The fusion protein of claim 18, wherein said fusion protein further comprises one or more chondrotin sulfate glycosaminoglycan ...http://www.google.es/patents/US5486599?dq=flatulence
Homeostatic properties of Lactobacillus jensenii engineered as a live vaginal anti-HIV microbicide | BMC Microbiology | Full...
... secretion of HIV-1 fusion inhibitors by lactobacilli. AIDS. 2006, 20 (15): 1917-1922. 10.1097/01.aids.0000247112.36091.f8. ... Levels of IL-1 receptor antagonist (IL-1RA) and the antimicrobial peptide secretory leukocyte protease inhibitor (SLPI) were ... M-tropic and dual T and M-tropic primary clinical strains of HIV-1 and T-tropic laboratory adapted strains of HIV-1 and HIV-2 ... natural CV-N protein interrupts HIV-1 membrane fusion by impairing CD4 independent and dependent binding of gp120 to the HIV-1 ...https://0-bmcmicrobiol-biomedcentral-com.brum.beds.ac.uk/articles/10.1186/1471-2180-13-4
US7122656B2 - Splice variant of MyD88 and uses thereof - Google Patents
Growth hormone antagonists WO1994025591A1 (en) 1993-04-29. 1994-11-10. Unilever N.V.. PRODUCTION OF ANTIBODIES OR ( ... Ribozyme gene therapy for hiv infection and aids US5545806A (en) 1990-08-29. 1996-08-13. Genpharm International, Inc.. ... Heterocyclic compounds useful as inhibitors of tyrosine kinases WO2001088137A2 (en) 2000-05-17. 2001-11-22. Immunex Corporation ... A viral vector is typically modified to have specificity for a given cell type by expressing a ligand as a fusion protein with ...https://patents.google.com/patent/US7122656?oq=6%2C163%2C776
HIV protease inhibitors, antibiotics, immunosuppressive agents, and β-adrenergic antagonists (Ford and Hait, 1993). This broad ... tubulovesicular movement of the fusion protein between the pericanalicular region and the bile canalicular membrane (Kipp and ... Virtually all of the drugs used to fight HIV infection penetrate the CNS poorly. Indeed, HIV protease inhibitors are substrates ... Dussault I, Lin M, Hollister K, Wang EH, Synold TW, and Forman BM (2001) Peptide mimetic HIV protease inhibitors are ligands ...http://pharmrev.aspetjournals.org/content/60/2/196
Patent US8107082 - SPR apparatus with a high performance fluid delivery system - Google Patents
Receptor based antagonists and methods of making and using. US6482593. 5 Nov 1998. 19 Nov 2002. Trustees Of Tufts College. ... Sulfated CCR5 peptides for HIV-1 infection. US20020127565. 15 Aug 2001. 12 Sep 2002. Sru Biosystems, Llc. Label-free high- ... Repressor-GCN4 Leucine Zipper Fusions" Science 250:1400-1403 (1990).. 8. Hyun et al., "Enzymatic Nanolithography of a self ... Bogoyevitch et al., "Peptide inhibitors of protein kinases-discovery, characterisation and use", Biochim. Biophys. Acta, 2005, ...http://www.google.co.uk/patents/US8107082
Frontiers | Novel Actions of Growth Hormone in Podocytes: Implications for Diabetic Nephropathy | Medicine
Tissue inhibitors of metalloproteases (TIPMs) are the known inhibitors of MMPs that are upregulated in the early pathogenesis ... administration of GHR antagonists also elicited renoprotective effect in diabetic rodent models. GHR antagonist (G120K-PEG) ... Morphologically podocyte injury is manifested by distortion and fusion of FPs, which leaves the GBM uncovered and such injury ... Podocyte loss has been reported in IgA nephropathy, HIV-associated nephropathy, and DN. Several studies have reported the ...https://www.frontiersin.org/articles/10.3389/fmed.2017.00102/full
Cancer chemotherapy - ribonucleases to the rescue
Some ribonuclease fusion proteins could be cytotoxic even if they are inhibited by RI . The targeting domain of a fusion ... Ribonuclease inhibitor. Remarkably, the most potent known inhibitor of RNase A, which is secreted from cells, is a cytosolic ... Inhibition of HIV-1 production and selective degradation of viral RNA by an amphibian ribonuclease. J Biol Chem. 1996;271:20783 ... Would a small-molecule antagonist of RI potentiate the cytotoxicity of exogenous or endogenous ribonucleases? The plethora of ...http://pubmedcentralcanada.ca/pmcc/articles/PMC2913432/
Integrin Targeted Therapeutics
Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J Med Chem. 1992;35:4640-2 ... Active PML infections resulting from JC virus are often seen immunocompromised individuals such as HIV patients. The increased ... α4β1 knockout mice are embryonic lethal and show disruption in placentation, defects in allantois-chorion fusion, cardiac ... Nonpeptide αvβ3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and ...http://thno.org/v01p0154.htm
Patent US8017749 - Compositions and methods to treat cancer with cupredoxins and CpG rich DNA - Google Patents
Drugs for treating HIV infection include, but are not limited to, reverse transcriptase inhibitors: AZT (zidovudine [Retrovir ... inhibitors with diuretics, angiotensin II receptor antagonists, calcium channel blockers, diuretics (including carbonic ... In addition, a derivative peptide may be a fusion of a polypeptide or fragment thereof to a chemical compound, such as but not ... farnesyl-protein transferase inhibitors; 5.alpha.-reductase inhibitors; inhibitors of 17β-hydroxysteroid dehydrogenase type 3; ...http://www.google.com/patents/US8017749?dq=5311516
Patent US7601814 - Reducing the immunogenicity of fusion proteins - Google Patents
Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional ... Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion ... Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. ... ENBREL or etanercept, a X-Fc fusion protein approved by the FDA, is a tumor necrosis factor (TNF) inhibitor used to treat ...http://www.google.ca/patents/US7601814
KEX2 Cleavage Regions OF Recombinant Fusion Proteins - Patent application
... fusions, IgM or IgA; interleukins, urokinase, chymase, and urea trypsin inhibitor, IGF-binding protein, epidermal growth factor ... a cd4+ t cell equivalent and the simultaneous detection of hiv infection via hiv antibody detection. ... METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS. 20120058114. ERBB2 antibodies comprising modular ... 4. The fusion DNA construct of claim 3, wherein X4 is V. 5. The fusion DNA construct of claim 3, wherein X3 is A. 6. The fusion ...http://www.patentsencyclopedia.com/app/20100055731
JoVE | Peer Reviewed Scientific Video Journal - Methods and Protocols
... one protein is expressed as a fusion with luciferase and the second as a fusion with YFP. An interaction between the two ... Here we present a novel method for assessing the in vitro replication of HIV-1 as influenced by the gag gene isolated from ... Biochemistry, Issue 85, Ubiquitin/proteasome system, 26S proteasome, protein degradation, proteasome inhibitor, Western ... agonist or antagonist behavior, or stability, relative to the native sequence. Protein design lies at the center of current ...https://www.jove.com/visualize/abstract/22110750/the-molecular-determinants-nedd8-specific-recognition-human
Download our free solidary book to support research on VHL disease